Endocrine Disorders: Evaluation and Management
Summary
- TZDs are considered second-line or third-line initial therapy for diabetes mellitus in the general population
- TZDs are associated with increased risk of congestive heart failure and are contraindicated in patients with a history of congestive heart failure and should be used with caution in those with cardiac risk factors
- Periodic monitoring of liver enzymes is also recommended due to risk of hepatotoxicity
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content